α-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination

W. S. Meng, L. H. Butterfield, A. Ribas, V. B. Dissette, J. B. Heller, Gustavo Miranda-Carboni, J. A. Glaspy, W. H. McBride, J. S. Economou

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

α-Fetoprotein (AFP) is a potential target for immunotherapy in hepatocellular carcinoma; both the murine and human T-cell repertoires can recognize AFP-derived epitopes in the context of the MHC. Protective immunity can be generated with AFP-engineered dendritic cell-based vaccines. We now report a DNA-based immunization strategy using a prime-boost approach: coadministration of plasmid DNA encoding murine AFP and murine granulocyte-macrophage colony-stimulating factor followed by boosting with an AFP-expressing nonreplicating adenoviral vector. This immunization strategy can elicit a high frequency of Th1-type AFP-specific cells leading to tumor protective immunity in mice at levels comparable with AFP-engineered dendritic cells. This cell-free mode of immunization is better suited for large-scale vaccine efforts for patients with hepatocellular carcinoma.

Original languageEnglish (US)
Pages (from-to)8782-8786
Number of pages5
JournalCancer Research
Volume61
Issue number24
StatePublished - Dec 15 2001

Fingerprint

Fetal Proteins
Adenoviridae
Immunity
Immunization
Vaccination
Plasmids
Dendritic Cells
Hepatocellular Carcinoma
Vaccines
Neoplasms
DNA
Granulocyte-Macrophage Colony-Stimulating Factor
Immunotherapy
Epitopes
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Meng, W. S., Butterfield, L. H., Ribas, A., Dissette, V. B., Heller, J. B., Miranda-Carboni, G., ... Economou, J. S. (2001). α-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Research, 61(24), 8782-8786.

α-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. / Meng, W. S.; Butterfield, L. H.; Ribas, A.; Dissette, V. B.; Heller, J. B.; Miranda-Carboni, Gustavo; Glaspy, J. A.; McBride, W. H.; Economou, J. S.

In: Cancer Research, Vol. 61, No. 24, 15.12.2001, p. 8782-8786.

Research output: Contribution to journalArticle

Meng, WS, Butterfield, LH, Ribas, A, Dissette, VB, Heller, JB, Miranda-Carboni, G, Glaspy, JA, McBride, WH & Economou, JS 2001, 'α-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination', Cancer Research, vol. 61, no. 24, pp. 8782-8786.
Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda-Carboni G et al. α-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Research. 2001 Dec 15;61(24):8782-8786.
Meng, W. S. ; Butterfield, L. H. ; Ribas, A. ; Dissette, V. B. ; Heller, J. B. ; Miranda-Carboni, Gustavo ; Glaspy, J. A. ; McBride, W. H. ; Economou, J. S. / α-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. In: Cancer Research. 2001 ; Vol. 61, No. 24. pp. 8782-8786.
@article{409e2404993f4cc9bf590632c75afec4,
title = "α-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination",
abstract = "α-Fetoprotein (AFP) is a potential target for immunotherapy in hepatocellular carcinoma; both the murine and human T-cell repertoires can recognize AFP-derived epitopes in the context of the MHC. Protective immunity can be generated with AFP-engineered dendritic cell-based vaccines. We now report a DNA-based immunization strategy using a prime-boost approach: coadministration of plasmid DNA encoding murine AFP and murine granulocyte-macrophage colony-stimulating factor followed by boosting with an AFP-expressing nonreplicating adenoviral vector. This immunization strategy can elicit a high frequency of Th1-type AFP-specific cells leading to tumor protective immunity in mice at levels comparable with AFP-engineered dendritic cells. This cell-free mode of immunization is better suited for large-scale vaccine efforts for patients with hepatocellular carcinoma.",
author = "Meng, {W. S.} and Butterfield, {L. H.} and A. Ribas and Dissette, {V. B.} and Heller, {J. B.} and Gustavo Miranda-Carboni and Glaspy, {J. A.} and McBride, {W. H.} and Economou, {J. S.}",
year = "2001",
month = "12",
day = "15",
language = "English (US)",
volume = "61",
pages = "8782--8786",
journal = "Cancer Research",
issn = "0008-5472",
number = "24",

}

TY - JOUR

T1 - α-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination

AU - Meng, W. S.

AU - Butterfield, L. H.

AU - Ribas, A.

AU - Dissette, V. B.

AU - Heller, J. B.

AU - Miranda-Carboni, Gustavo

AU - Glaspy, J. A.

AU - McBride, W. H.

AU - Economou, J. S.

PY - 2001/12/15

Y1 - 2001/12/15

N2 - α-Fetoprotein (AFP) is a potential target for immunotherapy in hepatocellular carcinoma; both the murine and human T-cell repertoires can recognize AFP-derived epitopes in the context of the MHC. Protective immunity can be generated with AFP-engineered dendritic cell-based vaccines. We now report a DNA-based immunization strategy using a prime-boost approach: coadministration of plasmid DNA encoding murine AFP and murine granulocyte-macrophage colony-stimulating factor followed by boosting with an AFP-expressing nonreplicating adenoviral vector. This immunization strategy can elicit a high frequency of Th1-type AFP-specific cells leading to tumor protective immunity in mice at levels comparable with AFP-engineered dendritic cells. This cell-free mode of immunization is better suited for large-scale vaccine efforts for patients with hepatocellular carcinoma.

AB - α-Fetoprotein (AFP) is a potential target for immunotherapy in hepatocellular carcinoma; both the murine and human T-cell repertoires can recognize AFP-derived epitopes in the context of the MHC. Protective immunity can be generated with AFP-engineered dendritic cell-based vaccines. We now report a DNA-based immunization strategy using a prime-boost approach: coadministration of plasmid DNA encoding murine AFP and murine granulocyte-macrophage colony-stimulating factor followed by boosting with an AFP-expressing nonreplicating adenoviral vector. This immunization strategy can elicit a high frequency of Th1-type AFP-specific cells leading to tumor protective immunity in mice at levels comparable with AFP-engineered dendritic cells. This cell-free mode of immunization is better suited for large-scale vaccine efforts for patients with hepatocellular carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0035893398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035893398&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 8782

EP - 8786

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 24

ER -